PP2A Cancerous-IN-1

Modify Date: 2024-01-20 10:33:36

PP2A Cancerous-IN-1 Structure
PP2A Cancerous-IN-1 structure
Common Name PP2A Cancerous-IN-1
CAS Number 1403933-79-8 Molecular Weight 488.54
Density N/A Boiling Point N/A
Molecular Formula C30H24N4O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of PP2A Cancerous-IN-1


PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].

 Names

Name PP2A Cancerous-IN-1

 PP2A Cancerous-IN-1 Biological Activity

Description PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].
Related Catalog
Target

pAKT

In Vitro PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1]. PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1]. PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1]. Cell Viability Assay[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced cell viability with a dose dependent manner. Western Blot Analysis[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced CIP2A expression. Apoptosis Analysis[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Induced cell apoptosis.
References

[1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.

 Chemical & Physical Properties

Molecular Formula C30H24N4O3
Molecular Weight 488.54